PDCD1 and metabolic dysfunction-associated steatohepatitis: Based on these observations, they hypothesize that CD8+PD1+ T cell-mediated tissue damage may underlie the promotion of hepatocarcinogenesis upon anti-PD1 treatment in NASH models.